References

Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden

10.1002/cncr.10593 · 2002 · External reference

Underrepresentation of patients 65years of age or older in cancer-treatment trials

10.1056/nejm199912303412706 · 1999 · External reference

Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups

10.1200/jco.2006.09.2759 · 2007 · External reference

Participation of patients 65years of age or older in cancer clinical trials

10.1200/jco.2003.08.010 · 2003 · External reference

Undertreatment strongly decreases prognosis of breast cancer in elderly women

10.1200/jco.2003.02.046 · 2003 · External reference

Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients

10.1001/archsurg.135.2.182 · 2000 · External reference

Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study

10.1200/jco.2002.08.062 · 2002 · External reference

Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study

10.1200/jco.20.1.173 · 2002 · External reference

Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993–1996

10.1016/s0895-4356(99)00098-0 · 1999 · External reference

Effect of age and comorbidity in postmenopausal breast cancer patients aged 55years and older

10.1001/jama.285.7.885 · 2001 · External reference

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer

10.1200/jco.2000.18.13.2529 · 2000 · External reference

Cancer statistics, 2009

10.3322/caac.20006 · 2009 · External reference

Colorectal cancer incidence in the United States, 1999–2004

10.1002/cncr.24216 · 2009 · External reference

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

10.1200/jco.1993.11.10.1879 · 1993 · External reference

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

10.7326/0003-4819-122-5-199503010-00001 · 1995 · External reference

Controlled trial of fluorouracil and low-dose leucovorin given for 6months as postoperative adjuvant therapy for colon cancer

10.1200/jco.1997.15.1.246 · 1997 · External reference

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

10.1056/nejmoa032709 · 2004 · External reference

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07

10.1200/jco.2006.08.2974 · 2007 · External reference

Adjuvant chemotherapy with uracil–tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial

10.1093/jjco/hyl014 · 2006 · External reference

Survival after postoperative combination treatment of rectal cancer

10.1056/nejm198611133152014 · 1986 · External reference

Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01

10.1093/jnci/80.1.21 · 1988 · External reference

Effective surgical adjuvant therapy for high-risk rectal carcinoma

10.1056/nejm199103143241101 · 1991 · External reference

Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer

10.1001/archinternmed.2007.82 · 2008 · External reference

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

10.1056/nejmoa010957 · 2001 · External reference

Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer

10.1001/jama.2010.272 · 2010 · External reference

Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer

10.1200/jco.2002.03.083 · 2002 · External reference

Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer

10.7326/0003-4819-136-5-200203050-00007 · 2002 · External reference

Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation

10.1001/jama.294.21.2703 · 2005 · External reference

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer

10.1200/jco.2006.06.9039 · 2006 · External reference

Effect of age on survival benefit of adjuvant chemotherapy in elderly stage III colon cancer patients: a population-based analysis

10.1200/jco.2008.26.15_suppl.4014 · 2008 · External reference

Inclusion of comorbidity into oncology data registries

1999 · External reference

The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus

10.1016/0021-9681(74)90017-4 · 1974 · External reference

Prognostic importance of comorbidity in a hospital-based cancer registry

10.1001/jama.291.20.2441 · 2004 · External reference

Differential prognostic impact of comorbidity

10.1200/jco.2004.08.040 · 2004 · External reference

Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer

10.1002/bjs.4913 · 2005 · External reference

Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity

10.1093/annonc/mdi159 · 2005 · External reference

Unresolved reference

2002 · External reference

Bayes factors

10.2307/2291091 · 1995 · External reference

Bayesian information criterion for censored survival models

10.1111/j.0006-341x.2000.00256.x · 2000 · External reference

Estimating the dimension of a model

10.1214/aos/1176344136 · 1978 · External reference

The central role of the propensity score in observational studies for causal effects

10.1093/biomet/70.1.41 · 1983 · External reference

The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer

10.1002/cncr.22726 · 2007 · External reference

Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice

10.1200/jco.2008.18.7443 · 2008 · External reference

Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer

10.1634/theoncologist.11-9-1025 · 2006 · External reference

Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity?

10.1200/jco.2007.15.9434 · 2008 · External reference

Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer

10.1016/j.jamcollsurg.2008.10.016 · 2009 · External reference

Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer

10.1002/cncr.23629 · 2008 · External reference

Comorbidity and functional status are independent in older cancer patients

10.1200/jco.1998.16.4.1582 · 1998 · External reference

Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study

10.1200/jco.20.2.494 · 2002 · External reference

Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years

10.1200/jco.2007.25.18_suppl.4007 · 2007 · External reference

Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT database

10.1200/jco.2009.27.15_suppl.4010 · 2009 · External reference